Zydus Cadila approved to market VaxiFlu 4 in India

Pharmaceutical firm Zydus Cadila has received approval from Indian regulators to market its tetravalent inactivated influenza vaccine for seasonal flu, VaxiFlu 4.

The drugmaker will become the first Indian pharma company and the second in the world to launch a vaccine of this type, which provides protection from the four influenza viruses: H1N1, H3N2, Type B (Brisbane) and Type B (Phuket).

The formula was developed at the Vaccine Technology Center in Ahmedabad. The group was previously responsible for the development, manufacture and launch of India’s first vaccine against H1N1, called Vaxiflu S.